{"filings":[{"id":96935,"accession_number":"0001193125-26-207530","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"FibroBiologics ups ATM offering to $7.5M; 71,830 shares sold to date","event_type":"other_material","confidence":"high","bullets":["Increased maximum aggregate offering price under ATM facility to $7.5 million.","71,830 shares of common stock sold to date under Sales Agreement with H.C. Wainwright & Co.","ATM offering uses existing S-3 shelf registration (effective Feb 10, 2025); prospectus supplement filed May 5, 2026.","Legal opinion and consent of Sichenzia Ross Ference Carmel LLP filed as exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96934,"accession_number":"0001193125-26-205044","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"FibroBiologics grants stock options to four top executives at $1.38 per share","event_type":"other_material","confidence":"high","bullets":["CEO Pete O'Heeron granted options for 92,410 shares; CFO, CSO, and General Counsel each granted 61,607 shares.","Vesting: 1/4th on first anniversary, then monthly over 36 months, subject to continuous service.","Total of 277,231 stock options granted under the 2022 Stock Plan on May 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96933,"accession_number":"0001193125-26-201376","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"FibroBiologics enters $6.15M ATM offering with H.C. Wainwright","event_type":"other_material","confidence":"high","bullets":["Up to $6.15M of common stock may be sold via at-the-market offering with H.C. Wainwright.","H.C. Wainwright receives 3.0% commission on gross proceeds plus $100K legal reimbursement.","Net proceeds used for working capital and general corporate purposes.","Shares will be sold under existing S-3 shelf (Reg. No. 333-284663).","Company not obligated to sell any shares; no assurance on price or timing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96932,"accession_number":"0001193125-26-164018","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FibroBiologics regains full compliance with Nasdaq listing requirements; monitoring periods imposed","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed compliance with $2.5M stockholders' equity rule (Mar 9) and $1.00 bid price rule (Apr 17).","One-year Mandatory Panel Monitor for both equity and bid price; failure during monitor triggers delist determination without cure period.","Company remains listed on Nasdaq Capital Market under symbol FBLG; all prior listing matters closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96931,"accession_number":"0001193125-26-161507","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"FibroBiologics amends bylaws to reduce stockholder quorum to one-third of voting power","event_type":"other","confidence":"high","bullets":["Board amended Section 2.07 of Bylaws to lower quorum from majority to one-third of voting power.","Amendment adopted on April 16, 2026, and effective immediately.","No other material items reported in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96930,"accession_number":"0001193125-26-149654","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"FibroBiologics terminates sublease early, saves ~$0.8M in rent","event_type":"other_material","confidence":"high","bullets":["Sublease for Webster, TX office terminated April 2, 2026, 18 months early; single payment of $45,108.25 resolves all rent obligations.","Company expects to save approx. $0.8 million in future rent payments through consolidation.","New principal executive office address is 9350 Kirby Drive, Suite 300, Houston, TX 77054, following 2025 opening of 10,000+ sq ft lab."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96927,"accession_number":"0001193125-26-149865","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K/A","filed_at":"2026-04-09T23:59:59+00:00","items":["1.02","1.01","8.01","9.01"],"status":"ready","headline":"FibroBiologics terminates sublease early, saves $0.8M in future rent; moves HQ to Houston","event_type":"other_material","confidence":"high","bullets":["Sublease buyout agreement with United Fire & Casualty terminates sublease effective April 2, 2026, 18 months early.","Single exit payment of $45,108.25 resolves remaining rent obligations; original sublease ran through Nov 30, 2027.","Expected savings of approx. $0.8 million in future rent payments.","Consolidation follows 2025 opening of new 10,000+ sq ft lab and office facility.","Principal executive offices relocated to 9350 Kirby Drive, Suite 300, Houston, TX 77054."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96929,"accession_number":"0001193125-26-142089","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"FibroBiologics implements 1-for-20 reverse stock split effective March 30, 2026","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1:20; every 20 shares converted to 1 share.","No fractional shares issued; any fractional interests rounded up to the nearest whole share.","Par value unchanged at $0.00001; authorized shares unchanged.","CUSIP changed to 31573L204; trading symbol remains 'FBLG'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96928,"accession_number":"0001193125-26-140044","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"FibroBiologics closes $3M public offering of common stock and warrants at $1.32/unit","event_type":"other_material","confidence":"high","bullets":["Offering of 2,272,728 shares (or pre-funded warrants) plus warrants, combined price $1.32/unit; net proceeds ~$2.5M after fees.","Warrants exercise price $1.32, exercisable only after stockholder approval; if fully cash-exercised, additional $3M proceeds possible.","Pre-funded warrants exercise price $0.00001, no expiration; beneficial ownership cap 9.99%.","Placement agent H.C. Wainwright received 7.0% cash fee, 1.0% management fee, and 159,091 placement agent warrants at $1.65.","Lock-up: insiders 30 days; company restricted from further equity issuance for 30 days and no variable-rate transactions for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111300,"accession_number":"0001193125-26-096474","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"FibroBiologics raises CFO Jason D. Davis base salary to $400,000","event_type":"other_material","confidence":"high","bullets":["CFO Jason D. Davis annual base salary increased to $400,000, effective January 1, 2026.","Target non-equity incentive compensation remains at 40% of base salary.","No other changes to CFO compensation or role were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111299,"accession_number":"0001193125-26-064040","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"FibroBiologics stockholders approve reverse stock split and warrant issuances","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at ratio between 1:5 and 1:30, with board discretion; 53.6M votes for, 1.3M against.","Issuance of up to 12.1M shares upon exercise of warrants from Nov 18, 2025 SPA approved (47.9M for, 1.2M against).","Issuance of up to 4.8M shares upon exercise of warrants from Nov 24, 2025 SPA and related engagement letter approved.","Issuance of up to 5.6M shares upon exercise of warrants from Dec 14, 2025 SPA and related engagement letter approved.","Adjournment proposal also passed; all five proposals approved at Feb 20, 2026 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111298,"accession_number":"0001193125-26-041187","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"FibroBiologics receives Nasdaq delisting notice for continued MVLS non-compliance","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified FibroBiologics on Feb 3, 2026 that continued failure to meet the $35M MVLS minimum adds a delisting basis.","The Panel will consider the company's plan to regain compliance with both the bid price and MVLS rules at a hearing.","FibroBiologics filed a proxy seeking shareholder approval for a reverse stock split (1:5 to 1:30) to address bid price deficiency.","Trading continues pending the Panel's decision; no assurance of an extension or successful compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111297,"accession_number":"0001193125-26-001077","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"FibroBiologics receives Nasdaq delisting notice for bid price non-compliance; plans hearing and reverse split vote","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified delisting on Dec 30, 2025, after 180-day cure period ended Dec 29 without compliance.","Company plans to request a hearing before the Nasdaq Hearings Panel to stay delisting.","Proxy filed Dec 29 seeking stockholder approval for reverse stock split (1-for-5 to 1-for-30).","No assurance of extension or successful regaining of compliance with $1.00 bid price rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127906,"accession_number":"0001193125-25-319441","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics raises ~$1.7M in registered direct offering at $0.33/share with warrants","event_type":"other_material","confidence":"high","bullets":["Sold 5,227,275 shares at $0.33/share; gross proceeds ~$1.7M; closing expected Dec 16, 2025.","Concurrent private placement of warrants to buy 5,227,275 shares at $0.33, exercisable only after stockholder approval, 5-year term.","CEO and prior purchaser entered voting agreements to support warrant share issuance under Nasdaq rules.","Placement agent H.C. Wainwright receives 7% cash fee and 365,909 warrants at $0.4125 per share.","Net proceeds for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127905,"accession_number":"0001193125-25-294634","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics raises $1.5M in registered direct offering priced at $0.335/share","event_type":"other_material","confidence":"high","bullets":["Sold 4,477,614 shares at $0.335/share; gross proceeds ~$1.5M before fees.","Concurrent private placement of 4,477,614 warrants at $0.335 exercise price; exercisable upon stockholder approval.","H.C. Wainwright placement agent gets 7.0% cash fee, 1.0% management fee, and 313,433 placement agent warrants at $0.4188.","Net proceeds for working capital and general corporate purposes.","30-day lock-up on equity issuances; one-year ban on Variable Rate Transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127904,"accession_number":"0001193125-25-288264","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"FibroBiologics raises ~$4M in registered direct offering paid in gold coins; redeems $3.4M note","event_type":"other_material","confidence":"high","bullets":["Priced 3,540,000 shares and 8,570,203 pre-funded warrants at $0.3303/unit, gross proceeds ~$4M.","Payment in sovereign-issued .9999 fine gold coins valued at $4,069.18/oz, intent to liquidate to USD.","Concurrent private placement of 12,110,203 warrants at $0.3303, exercisable after stockholder approval.","Redeemed final Promissory Note (third tranche) of $3.4M principal plus 6% premium for total $3.604M.","Net proceeds for general corporate purposes, including debt satisfaction; offering closes Nov. 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144678,"accession_number":"0000950170-25-105807","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"FibroBiologics receives Nasdaq MVLS deficiency notice; 180-day cure period to Feb 2026","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified FibroBiologics on Aug 4, 2025 that its MVLS fell below the $35M minimum for continued listing.","Company has until Feb 2, 2026 to regain compliance by having MVLS close at $35M+ for 10 consecutive business days.","No immediate impact on listing; stock continues trading on Nasdaq Capital Market under symbol FBLG.","If compliance is not regained by Feb 2, 2026, Nasdaq may initiate delisting, subject to appeal.","Company will monitor MVLS and consider available options to address the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144677,"accession_number":"0000950170-25-096914","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"FibroBiologics converts $1.4M of notes, issues 2.15M shares at ~$0.65 avg price","event_type":"other_material","confidence":"high","bullets":["On June 20-27 and July 15, 2025, YA II PN converted $1.4M of Second and Third Notes into 2,154,530 common shares.","Conversion prices ranged from $0.5624 to $0.6934 per share; Second Note fully converted, Third Note has $3.9M remaining.","First Note retains full $5.0M principal; total remaining note balance across all three is $8.9M.","Shares issued in reliance on Section 4(a)(2) exemption; no public offering involved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144675,"accession_number":"0000950170-25-096923","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K/A","filed_at":"2025-07-18T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"FibroBiologics amends 8-K to disclose up to 41.4M shares issuable under SEPA with YA II PN","event_type":"other_material","confidence":"high","bullets":["Maximum shares convertible from $15M promissory notes: 36,945,812 shares at $0.406/share.","Additional maximum shares from Commitment Amount: 4,424,778 shares at $2.26/share.","Agreement with YA II PN, Ltd. was previously disclosed on Dec 20, 2024; amendment adds share counts.","Conversion price subject to anti-dilution adjustments; shares unregistered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144676,"accession_number":"0000950170-25-093832","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"FibroBiologics receives Nasdaq bid price deficiency notice; 180 days to cure","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified FibroBiologics on July 1, 2025 that common stock closing bid price was below $1.00 for 30 consecutive trading days.","Company has until December 29, 2025 to regain compliance by maintaining $1.00+ closing bid for 10 consecutive business days.","If not cured by deadline, FibroBiologics may qualify for a second 180-day period subject to meeting other listing standards.","Failure to cure could lead to delisting; Company may consider options to regain compliance, no guarantee of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163080,"accession_number":"0001641172-25-015282","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics closes $5M third tranche of $25M SEPA with Yorkville; funds for R&D and diabetic foot ulcer trial","event_type":"other_material","confidence":"high","bullets":["Third $5M tranche of $15M pre-paid advance drawn; total $15M now under SEPA with YA II PN, Ltd.","Convertible promissory note: 0% interest (18% on default), matures Dec 20, 2025, convertible at lower of $0.9801 or 94% of 5-day VWAP.","Proceeds for general corporate purposes, including R&D and Phase 1/2 diabetic foot ulcer trial expected H2 2025.","Company may sell additional $10M common stock to Yorkville with consent while notes outstanding.","Conversion limited to 4.99% beneficial ownership cap; prior conversions totaled $5.7M principal at varying prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163079,"accession_number":"0001641172-25-015065","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"FibroBiologics stockholders approve capital stock increase and share issuance to YA II PN","event_type":"other_material","confidence":"high","bullets":["Authorized capital stock increased via amendment to certificate of incorporation effective June 12, 2025.","Stockholders elected Matthew Link and Victoria Niklas, M.D. as Class II directors until 2028.","Ratified WithumSmith+Brown, PC as independent auditor for FY 2025; votes: 53,940,908 for, 73,899 against, 528,109 abstain.","Approved issuance of common stock to YA II PN, LTD., exceeding 7,013,635 shares under Standby Equity Purchase Agreement.","Proxies representing 54,542,916 votes (77.4% of eligible) were present at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163078,"accession_number":"0001641172-25-014296","cik":1958777,"company_name":"FibroBiologics, Inc.","ticker":"FBLG","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"FibroBiologics appoints Jason D. Davis, CPA, as CFO; base salary $350k","event_type":"leadership","confidence":"high","bullets":["Jason D. Davis appointed CFO effective June 9, 2025; previously CFO at Virax Biolabs, led IPO in July 2022.","Employment agreement includes base salary of $350k, annual bonus up to 40% of base, and sign-on cash bonus of $15k.","Received option grant of 450,000 shares under 2022 Stock Plan; vests 1/4 on first anniversary, then monthly.","Davis has 20+ years finance experience; at HyperDynamics increased market cap from $20M to $700M and raised $200M+.","Appointment comes as FibroBiologics advances toward Phase 1/2 clinical trial for diabetic foot ulcers in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}